NEW YORK (Reuters) - Amgen Inc said it expects generic versions of biotech drugs, known as biosimilars, to be a multibillion-dollar opportunity for the company and has targeted some of the industry's biggest sellers, including the main rivals for its own blockbuster rheumatoid arthritis drug Enbrel. The company on Thursday also said that between this year and 2016 it will have key late-stage data from eight experimental medicines. ... Courtesy of Yahoo News
No comments:
Post a Comment